<DOC>
	<DOCNO>NCT01896232</DOCNO>
	<brief_summary>The purpose study demonstrate treatment etelcalcetide ( AMG 416 ) inferior treatment cinacalcet lower serum parathyroid hormone ( PTH ) level &gt; 30 % baseline among patient chronic kidney disease ( CKD ) secondary hyperparathyroidism ( SHPT ) require management hemodialysis .</brief_summary>
	<brief_title>Head-to-Head Study Etelcalcetide ( AMG 416 ) Cinacalcet</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>Eligible subject must receive adequate thrice weekly maintenance hemodialysis dialysate calcium concentration ≥ 2.5 mEq/L least 3 month prior screen laboratory assessment Subjects must SHPT define one central laboratory screen predialysis serum PTH value &gt; 500 pg/mL , measure separate day within 2 week prior randomization Subjects must one serum cCa value ≥ 8.3 mg/dL obtain dialysis within 2 week date randomization Subjects receive calcium supplement must maximum dose change 50 % within 2 week screen laboratory assessment obtain , dose must remain unchanged randomization Eligible subject receive cinacalcet 3 month precede first screen laboratory assessment Other criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Secondary Hyperparathyroidism , renal , kidney , kidney , dialysis , hemodialysis , chronic kidney disease , CKD , SHPT</keyword>
</DOC>